PMID: 9190982Jun 1, 1997Paper

Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest

Gynecologic Oncology
M BruzzoneP F Conte

Abstract

From June 1990 to October 1994, 111 advanced ovarian cancer patients with minimal (less than 2 cm) residual disease after platinum-based front-line chemotherapy and second-look laparotomy entered a cooperative randomized study aimed at evaluating the effectiveness and the toxicity of the addition of interferon-alpha2 to carboplatin, both intraperitoneally (ip) administered. Patients were randomized to receive either 3 courses of ip Carboplatin 400 mg/m2 Day 1 q 28 days (54 pts) (CBDCA) or ip interferon-alpha 25 x 10(6) U Day 1 + ip carboplatin 400 mg/m2 Day 2 q 28 days (57 pts) (CBDCA + IFN). Patients treated with interferon experienced more severe (WHO grade 3-4) leukopenia (28% vs 17.1%) and anemia (14% vs 4.2%). Fever (P = 0.000) and flu-like syndrome (P = 0.02) were significantly more frequent in the combination arm. No difference in gastroenteric, neurologic, or renal toxicity was observed. At a median follow-up time of 13 months (range 1-72) 71 patients showed a disease progression (31 CBDCA, 40 CBDCA + IFN) and 44 patients died (21 CBDCA, 23 CBDCA + IFN). Median progression-free survival was 11 months in the CBDCA group and 10 months in the CBDCA + IFN arm. Median survival was 22 and 29 months in CBDCA and CBDCA + IFN ar...Continue Reading

References

Jan 1, 1992·Oncology·M O NicolettoS Monfardini
Feb 1, 1992·American Journal of Clinical Oncology·A de GramontJ Cady
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H WillemseN H Mulder
Mar 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H WillemseD T Sleijfer
Sep 21, 1988·Journal of the National Cancer Institute·M J PiccartG Atassi
Jan 1, 1981·Cancer·A B MillerA Winkler

❮ Previous
Next ❯

Citations

Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P F ConteC Cianci
May 14, 2009·Therapeutics and Clinical Risk Management·Maurie Markman
Aug 10, 2007·Expert Opinion on Investigational Drugs·Daniela Matei
Jun 7, 2013·The Cochrane Database of Systematic Reviews·Aramide O LawalLiesl Grobler
Dec 21, 2000·Current Oncology Reports·C S Chu, S C Rubin
Feb 6, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A Gadducci, P F Conte
Nov 1, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sundar SanthanamKen O'Byrne
Jan 9, 2019·Journal of Gastrointestinal Cancer·Keishla M GarcíaÁngel M Rodríguez
Feb 27, 1999·Current Opinion in Obstetrics & Gynecology·S MakhijaR R Barakat
Mar 17, 2012·Clinical Pharmacokinetics·Csilla Hasovits, Stephen Clarke
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yumi TakemotoMasamichi Kojiro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.